drugset / Trial / NCT05032391
Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization
RandomizedParallel-groupDouble-blindPrevention
Summary
The first multicenter prospective, randomized, double-blind, placebo-controlled clinical trial of the pentavalent live vaccine for RVI prevention was conducted in Russia among healthy infants aged 2 months at the time of the first vaccination.
Timeline
- Start
- 2019-02-22
- Primary completion
- 2019-09-22
- Completion
- 2019-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | The pentavalent rotavirus vaccine | Vaccine | 2.5 ml | Oral |